Emboline Raises $20M for Stroke Prevention Medical Device

Emboline, Inc. has successfully secured $20 million in growth capital, with Trinity Capital Inc. leading the investment round. This significant funding infusion is earmarked to accelerate the commercial rollout of Emboline's innovative Emboliner® Embolic Protection System, a device designed to mitigate the risk of stroke and neurological damage during complex cardiovascular interventions like transcatheter aortic valve replacement (TAVR).

The financing comes at a critical juncture for Emboline, following the recent completion of patient enrollment in its pivotal IDE clinical trial, PROTECT H2H. This study is instrumental in evaluating the efficacy of the Emboliner® system. The capital injection will directly support the company's strategic preparations for market entry in both the United States and Europe, anticipated later this year, alongside ongoing advancements in its broader embolic protection technology portfolio.

The Emboliner® system represents a significant advancement in patient safety for structural heart procedures. It is engineered to capture and remove embolic debris that can dislodge during interventions, preventing it from reaching the brain or other vital organs. Emboline's commitment to this field is further underscored by its robust intellectual property portfolio, which encompasses diverse approaches to aortic embolic filtration and deflection.

Market analysis indicates a growing demand for advanced neuroprotection solutions in interventional cardiology. The global TAVR market, for instance, is projected to expand substantially, driven by an aging population and the increasing adoption of minimally invasive techniques. Within this expanding market, technologies that demonstrably reduce procedural risks, such as stroke, are poised for significant uptake. Emboline's technology directly addresses this critical unmet need, potentially reshaping procedural standards.

Results from the PROTECT H2H trial are slated for presentation at the prestigious American College of Cardiology Annual Scientific Session on March 29, 2026. This upcoming data release is expected to generate considerable interest from the medical community and further validate the clinical potential of the Emboliner® system. Scott Russell, President and CEO of Emboline, expressed enthusiasm for the partnership with Trinity Capital, highlighting how the funding positions the company for its upcoming commercial phase and its mission to equip physicians with comprehensive embolic protection.

Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, commented on the investment, emphasizing the system's potential to enhance physician confidence and improve patient outcomes. Trinity Capital, known for its expertise in providing tailored debt solutions to growth-oriented companies, has deployed over $5.5 billion across more than 463 investments since its inception in 2008, demonstrating a strong track record in supporting innovative ventures within the life sciences sector.